Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other financing activities (2018 - 2024)

Crinetics Pharmaceuticals has reported Other financing activities over the past 3 years, most recently at -$967000.0 for Q4 2024.

  • For Q4 2024, Other financing activities fell 125.41% year-over-year to -$967000.0; the TTM value through Dec 2025 reached $3.4 million, up 14.65%, while the annual FY2024 figure was $15.0 million, 57523.08% up from the prior year.
  • Other financing activities for Q4 2024 was -$967000.0 at Crinetics Pharmaceuticals, down from $4.3 million in the prior quarter.
  • Over five years, Other financing activities peaked at $4.3 million in Q1 2024 and troughed at -$967000.0 in Q4 2024.